Vogel CW, Fritzinger DC, Gorsuch WB et al. Complement depletion with humanised cobra venom factor: efficacy in preclinical models of vascular diseases. Thromb Haemost 2015;113:548-52
Vogel CW, Finnegan PW, Fritzinger DC. Humanized cobra venom factor: structure, activity, and therapeutic efficacy in preclinical disease models. Mol Immunol 2014;61:191-203
Huda R, Fritzinger DC, Finnegan PF, et al. Complement depletion with humanized Cobra Venom Factor (CVF) improves the severity of Experimental Autoimmune Myasthenia Gravis (EAMG). Mol Immunol 2011;48:1712
Fritzinger DC, Dean R, Meschter C, et al. Complement depletion with humanized cobra venom factor in a mouse model of age-related macular degeneration. Adv Exp Med Biol 2010;703:151-62
Fritzinger DC, Damaj BB, Wong K, et al. Pharmacokinetics of humanized cobra venom factor in mice. Mol Immunol 2010;47:2268-2269
Vogel C-W, Fritzinger DC. Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon 2010;56:1198-1222
Wang SY, Veeramani S, Racila E, et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009;114:5322-30
Gorsuch WB, Guikema BJ, Fritzinger DC, et al. Humanized cobra venom factor decreases myocardial ischemia-reperfusion injury. Mol Immunol 2009;47:506-10
Fritzinger DC, Hew BE, Thorne M, et al. Functional characterization of human C3/cobra venom factor hybrid proteins for therapeutic complement depletion. Dev Comp Immunol 2009;33:105–116
Fritzinger DC, Ferreira VP, Hew BE, et al. A novel concept for the treatment of paroxysmal nocturnal haemoglobinuria (PNH): complement depletion with a human C3 derivative with cobra venom factor-like activity prevents lysis of PNH erythrocytes. Mol Immunol 2008;45:4177
Fritzinger DC, Hew BE, Lee JQ, et al. Human C3/cobra venom factor hybrid proteins for therapeutic complement depletion: in vivo activity and lack of toxicity in primates. Mol Immunol 2008;45:4112
Fritzinger DC, Hew BE, Lee JQ, et al. Derivatives of human complement component C3 for therapeutic complement depletion: a novel class of therapeutic agents. Adv Exp Med Biol 2008;632:293-307
Vogel CW, Fritzinger DC. Humanized cobra venom factor: experimental therapeutics for targeted complement activation and complement depletion. Curr Pharm Des 2007;13:2916-26
Fritzinger DC. Cancer research center hotline: complement depletion: use of human C3/cobra venom factor (CVF) chimeric proteins as therapeutic agents. Hawaii Med J 2005;64:133-4, 137
Fritzinger DC, Benjamin DE. The Complement System in Neuropathic and Postoperative Pain. Open Pain J. 2016 ; 9: 26–37
Brucato FH, Benjamin DE. Synaptic Pruning in Alzheimer's Disease:Role of the Complement System. Global Journal of Medical Research F:Diseases 2020;Volume 20 Issue 6 Version1.0. ISSN: 2249-4618 & Print ISSN:0975-5888
